Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech to develop novel oral COVID-19 vaccine candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
XyloCor Therapeutics closed an additional $22.6 million in its oversubscribed Series A financing round that will support the development of its lead gene therapy program for patients with refractory angina, a coronary artery disease.
A giant in the world of oncology has fallen. José Baselga, whose research paved the way for new treatments in different types of cancer, died Sunday.
The investment made to build this end-to-end cell culture biopharmaceutical contract development and manufacturing organization facility clocked in at approximately $2 billion.
Merck and Eisai announced that their combination of Merck’s checkpoint inhibitor Keytruda and Eisai’s Lenvima, a tyrosine kinase inhibitor, significantly improved progression-free survival in advanced endometrial cancer.
Two years after uBiome announced it was filing for bankruptcy and closing its doors, the company’s co-founders and former co-chief executive officers have been indicted for fraud and money laundering.
The U.S. Senate confirmed Xavier Becerra as Secretary of the Department of Health and Human Services in a 50-49 vote.
European genetic studies aren’t particularly accurate when applied to Middle East populations, according to new research from the Qatar Foundation.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.